Reactor Panel

October 20 at 10:30am-11:30am

Panelists will discuss key points made during Director King’s remarks while also providing their own perspectives on the current state of tobacco and nicotine product regulation, policy, compliance, and enforcement in the U.S.

Moderator: Stacy L. Ehrlich, Partner, Kleinfeld, Kaplan & Becker LLP

Panelists:
Robin J. Mermelstein, Distinguished Professor of Psychology and Director, Institute for Health Research and Policy, University of Illinois-Chicago
Matthew L. Myers, President, Campaign for Tobacco-Free Kids
Barry S. Schaevitz, Partner, Fox Rothschild LLP

Novel Products and Future Innovation: How Would New or Streamlined Pathways to Market Impact Public Health?

October 21 at 2:30pm-3:40pm

Bringing a new tobacco or nicotine product to market is costly and time-consuming, and many have argued the process is inaccessible for smaller companies and will stifle future innovation. Panelists will address the practical side of the PMTA and Substantial Equivalence (SE) pathways and how CTP could lessen the burden of bringing a product to market, while also considering whether a wider array of products would increase public health risks, including greater nicotine use among youth and young adults.

Moderator: Beth G. Oliva, Partner, Fox Rothschild LLP

Panelists:
Kimberly Agnew-Heard, Director, PMTA Submissions, Altria Client Services
Azim Chowdhury, Partner, Keller and Heckman LLP
Dorothy K. Hatsukami, Professor, Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School

Please note there is a cost to attend.

CLE credit available.